Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An important step toward advancing vaccines for human use, a recent study has shown that inhaled vaccines could potentially improve efficiency and reduce viral transmission.

Medical practitioner using mask inhaler on a patient

Interest in administering vaccines mucosally, rather than by intramuscular injections, has been growing since the SARS-CoV-2 pandemic was declared in 2020. 

Working in collaboration, scientists from the Pandemic Sciences Institute and The Pirbright Institute used pigs as a model to explore immune system responses to mucosally-administered flu vaccines, which target viruses at the point of entry.

Comprehensive measurement of immune responses in human lungs is not possible. To overcome this challenge, the researchers used pigs - whose respiratory tract is anatomically and functionally similar to that of humans - as a model to define key immune responses. 

Samples collected from both the lungs and blood of vaccinated pigs, aided by mathematical modelling, showed that lung responses can be predicted from blood tests, making it easier to assess vaccine effectiveness in humans.

Principal investigator Professor Dame Sarah Gilbert, Saïd Professor of Vaccinology at the Pandemic Sciences Institute, said: ‘The research found that immune responses in the blood could reliably reflect those in the lungs, thus offering a practical way to assess the effectiveness of vaccines targeting the respiratory system. The findings provide critical insights into how immune responses can be measured from easily accessible blood samples and are a foundation for future testing of mucosally administered vaccines in clinical trials.’

 

Read the full story on the Nuffield Department of Medicine website.

 

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.